Insulin like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia

British Journal of Cancer

Volumn 76, Issue 9, 1997, Pages 1115-1118

  Mantzoros, C S ^a,b   Tzonou, A ^c   Signorello, L B ^a   Stampfer, M ^a   Trichopoulos, D ^a,e   Adami, H O ^a,d  

^a HARVARD CENTER FOR CANCER PREVENTION   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d KAROLINSKA INSTITUTE   (Sweden)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN C; STEROID HORMONE;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BLOOD SAMPLING; CANCER RISK; CONTROLLED STUDY; DEMOGRAPHY; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RADIOIMMUNOASSAY; REGRESSION ANALYSIS; STATISTICS;

EID: 0030799934     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.520     Document Type: Article

References (20)

1. Angelloz-Nicoud P and Binoux M (1995) Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3). Endocrinology 136: 5485-5492
2. Breslow NE and Day NE (1980) Statistical Methods in Cancer Research. Vol. 1 The Analysis of Case Control Studies, IARC Scientific Publication 32. International Agency for Research on Cancer: Lyon
3. Burfeind P, Chernicky CL, Rininsland F, Han J and Ilan J (1996) Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci USA 93: 7263-7268
4. Cohen P, Peehl DM, Lamson G and Rosenfeld RG (1991) Insulin-like growth factors, IGF receptors and IGF binding proteins in primary culture of prostate epithelial cells. J Clin Endocrinol Metabol 73: 401-407
5. Cohen P, Peehl DM, Stamey TA, Wilson KF, Clemmons DR and Rosenfeld RG (1993) Elevated levels of insulin-like growth factor binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab 76: 1031-1035
6. Daughaday WH (1990) The possible autocrine/paracrine and endocrine roles of insulin like growth factors of human tumors. Endocrinology 127: 1-4
7. Ezzat S and Melmed S (1991) Are patients with acromegaly at increased risk for neoplasia? J Clin Endocrinol Metab 72: 245-249
8. Geller J (1993) Basis for hormonal management of advanced prostate cancer. Cancer 71: 1039-1045
9. Geller J (1995) Approach to chemoprevention of prostate cancer. J Clin Endocrinol Metab 80: 717-719
10. Goustin AS, Leof EB, Shipley GD and Moses HL (1986) Growth factors and cancer. Cancer Res 46: 1015-1029
11. Kanety H, Madjar Y, Dagan Y, Levi J, Papa MZ, Pariente C, Goldwaser R and Karasik A (1993) Serum insulin-like growth factor binding protein-2 (IGF BP-2) is increased and IGF BP-3 is decreased in patients with prostate cancer: Correlation with serum prostate specific antigen. J Clin Endocrinol Metab 77: 229-233
12. Kimura G, Kasuya J, Giannini S, Honda Y, Mohan S, Kawachi M, Akimoto M and Fujita-Yamaguchi Y (1996) Insulin-like growth factor (IGF) system components in human prostatic cancer cell-lines: LNGaP. DU145, PC-3 cells. Int J Urol 3: 39-46
13. Lagiou P, Mantzoros CS, Tzonou A, Signorello LB, Lipworth L and Trichopoulos D (1997) Serum steriods in relation to benign prostatic hyperplasia. Oncology (in press)
14. Leroith D, Clemmons D, Nissley P and Rechler MM (1992) NIH Conference. Insulin-like growth factors in health and disease. Ann Intern Med 116: 854-862
15. Miglietta L, Barreca A, Repetto L, Constantini M, Rosso R and Boccardo F (1993) Suramin and serum insulin-like growth factor levels in metastatic cancer patients. Anticancer Res 13: 2473-2476
16. Montie JE and Pienta K (1994) Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer. Urology 43: 892-898
17. Pietrzkowski Z, Mulholland G, Gomella L, Jameson BA, Wernicke D and Baserga R (1993) Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor I. Cancer Res 53: 1102-1106
18. Signorello LB, Tzonou A, Mantzoros CS, Lipworth L, Lagiou P, Hsieh C-c, Stampfer M and Trichopoulos D (1997) Serum steroids in relation to prostate cancer risk in a case control study (Greece). Cancer Causes Control (in press)
19. Webster NJ, Resnik JL, Reichart DB, Strauss B, Haas M and Seely BL (1996) Repression of the insulin receptor promoter by the tumor suppressor gene product p53: a possible mechanism for receptor overexpression in breast cancer. Cancer Res 56: 2781-2788
20. Weiderpass E, Gridley G, Persson I, Nyren O, Ekbom A, Hoover R and Adami HO (1997) Risk of endometrial and breast cancer in patients with diabetes mellitus. Int J Cancer 71: 360-363